Search research articles
Contact Us
Filters
Showing results (101-110 of 208) with videos related to
Page
of 21
Sort By:
European Urology
|
September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
Himisha Beltran, Adam Jendrisak, Mark Landers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2019
Clinical features of neuroendocrine prostate cancer
Vincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
Cancer Research
|
July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer
Medha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology
|
July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer
Jaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Plos One
|
January 4, 2014
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow
Gunjan Gakhar, Vicente N Navarro, Madelyn Jurish, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 14, 2019
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer
Michael Karass, Rohan Bareja, Ethan Shelkey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 16, 2016
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma
Michael J P Crowley, Theresa Scognamiglio, Yi-Fang Liu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 1, 2024
Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomes
Giuseppe Galletti, Ahmed Halima, Ada Gjyrezi, et al.
BMC Cancer
|
August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
Page
of 21
Search research articles
Search
Showing results (101-110 of 208) with videos related to
Sort By:
Page
of 21
European Urology
|
September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
Himisha Beltran, Adam Jendrisak, Mark Landers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2019
Clinical features of neuroendocrine prostate cancer
Vincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
Cancer Research
|
July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer
Medha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology
|
July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer
Jaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Plos One
|
January 4, 2014
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow
Gunjan Gakhar, Vicente N Navarro, Madelyn Jurish, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 14, 2019
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer
Michael Karass, Rohan Bareja, Ethan Shelkey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 16, 2016
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma
Michael J P Crowley, Theresa Scognamiglio, Yi-Fang Liu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 1, 2024
Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomes
Giuseppe Galletti, Ahmed Halima, Ada Gjyrezi, et al.
BMC Cancer
|
August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
Page
of 21